DGAP-News: MorphoSys AG / Key word(s): Conference MorphoSys to Present at Upcoming Conference 10.02.2017 / 11:00 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Planegg/Munich, Germany, February 10, 2017 MorphoSys to Present at Upcoming Conference MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) will present at the following conference: LEERINK Partners 6th Annual Global Healthcare Conference Date: February 16, 2017, 3:30 pm EST (9:30 pm CET, 8:30 pm GMT) Venue: New York, USA Presenter: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG A PDF version of the presentation will be provided at www.morphosys.com. The link to the webcast will be filed under www.morphosys.com/conference- calls. About MorphoSys: MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare. Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http:// www.morphosys.com. HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R), arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio Pharma(R) and LanthioPep(R) are registered trademarks of the MorphoSys Group. This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward- looking statements as far as the wording of the relevant press release is concerned. For more information, please contact: MorphoSys AG Anke Linnartz Head of Corporate Communications & IR Jochen Orlowski Associate Director Corporate Communications & IR Alexandra Goller Senior Manager Corporate Communications & IR Tel: +49 (0) 89 / 899 27-404 [email protected] --------------------------------------------------------------------------- 10.02.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: MorphoSys AG Semmelweisstr. 7 82152 Planegg Germany Phone: +49 (0)89 899 27-0 Fax: +49 (0)89 899 27-222 E-mail: [email protected] Internet: www.morphosys.com ISIN: DE0006632003 WKN: 663200 Indices: TecDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange End of News DGAP News Service --------------------------------------------------------------------------- 543651 10.02.2017